Clinical Trials Browser

Phase 2 × Multiple Myeloma × masitinib × Clear all

NCT00866138 2019-12-03

Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3

Phase 2 Completed

Multiple Myeloma, Recurrence